Quick Summary
- Cigna delivered Q1 adjusted EPS of $7.79, surpassing analyst expectations of $7.60
- Quarterly revenue climbed 5% to $68.5 billion, exceeding forecasts of $66.3 billion
- The company increased full-year 2026 EPS outlook to a minimum of $30.35, representing a $0.10 boost
- Shares declined approximately 3% following the announcement, with pharmacy operations cited as a concern
- Leadership transition underway as CEO David Cordani steps down July 1; COO Brian Evanko assumes top role
The health insurance giant delivered impressive first-quarter results, yet investors responded with skepticism. Despite exceeding earnings and revenue projections while raising its annual forecast, Cigna experienced a share price decline.
CIGNA $CI Q1’26 EARNINGS HIGHLIGHTS
🔹 Adj. Revenue: $68.52B (Est. $66.24B) 🟢; +5% y/y
🔹 Adj. Operating EPS: $7.79 (Est. $7.61) 🟢
🔹 Healthcare Adj. Revenue: $11.48B (Est. $11.37B) 🟢
🔹 Healthcare Medical Care Ratio: 79.8% (Est. 81.0%) 🟢
🔹 FY Adj. Operating EPS Guide: At…— Wall St Engine (@wallstengine) April 30, 2026
First-quarter adjusted earnings per share reached $7.79, representing an increase from last year’s $6.74 and surpassing analyst projections of $7.60. Total revenue touched $68.5 billion, marking a 5% year-over-year gain and exceeding the anticipated $66.3 billion figure.
Management also elevated its full-year 2026 adjusted EPS projection to a minimum of $30.35, marking a $0.10 improvement over previous estimates. This updated midpoint marginally surpasses the Street consensus of $30.33.
Notwithstanding these achievements, shares tumbled approximately 3% to the $283 range during morning trading.
Adjusted operating income expanded 12% to $2.1 billion, up from $1.8 billion in the prior-year period. The improvement was primarily attributed to performance within Cigna Healthcare and Evernorth Health Services divisions.
The Cigna Healthcare segment saw pre-tax adjusted operating income surge 18% to $1.5 billion. The division’s medical care ratio enhanced to 79.8%, representing an improvement from the previous year’s 82.2% figure.
Evernorth posted adjusted revenues of $58.4 billion, reflecting a 9% year-over-year increase. The Specialty and Care Services segment generated income of $1.1 billion, up 20% from the comparable period.
PBM Operations Face Headwinds
The pharmacy benefit management division represented the quarter’s soft spot. TD Cowen analyst Charles Rhyee characterized it as the “only blemish” within an otherwise solid report, though he emphasized this weakness was anticipated following comparable challenges at UnitedHealth and Elevance Health. His Buy rating remains intact with a $338 target price.
Leerink Partners analyst Whit Mayo maintained a Market Perform stance, noting that outcomes “look fine” while observing that “not much jumps off the page as particularly surprising.”
The company has been restructuring its pharmacy benefit management operations since autumn, transitioning toward a “rebate-free” framework in response to heightened regulatory scrutiny and public backlash regarding pharmaceutical pricing strategies.
Executive Suite Changes Create Questions
This past February, Cigna’s Express Scripts division became the initial major PBM to reach a settlement with the Federal Trade Commission concerning insulin pricing litigation. The agreement involved no admission of wrongdoing and complemented the previously announced rebate-free approach.
The organization is simultaneously navigating an executive transition. Long-time CEO David Cordani plans to retire effective July 1, with current COO Brian Evanko positioned to assume the chief executive position.
The convergence of operational transformation initiatives, executive succession, and measured analyst sentiment clarifies why impressive quarterly performance failed to generate upward stock momentum.
The quarter’s most encouraging indicators included medical care ratio enhancement and robust organic expansion within specialty service operations.
